128 related articles for article (PubMed ID: 35878517)
21. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
[TBL] [Abstract][Full Text] [Related]
22. Enhancing tumour content and tumour cell count using microdissection contributes to higher detection rate of genetic mutations by next-generation sequencers.
Tamiya A; Kanaoka K; Inagaki Y; Taniguchi Y; Nakao K; Matsuda Y; Okishio K; Takeda M; Kasai T; Shigeki S
Heliyon; 2023 Nov; 9(11):e22082. PubMed ID: 38027827
[TBL] [Abstract][Full Text] [Related]
23. Multiplex gene-panel testing for lung cancer patients.
Yatabe Y; Sunami K; Goto K; Nishio K; Aragane N; Ikeda S; Inoue A; Kinoshita I; Kimura H; Sakamoto T; Satouchi M; Shimizu J; Tsuta K; Toyooka S; Nishino K; Hatanaka Y; Matsumoto S; Mikubo M; Yokose T; Dosaka-Akita H
Pathol Int; 2020 Dec; 70(12):921-931. PubMed ID: 32956529
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
25. [Current Status and Issues of Companion Diagnostics for Non-Small Cell Lung Cancer].
Satouchi M
Gan To Kagaku Ryoho; 2024 Apr; 51(4):378-382. PubMed ID: 38644300
[TBL] [Abstract][Full Text] [Related]
26. Nucleic Acid Quality Assessment is Critical to the Success of the Oncomine Dx Target Test for Lung Cancer.
Nagakubo Y; Hirotsu Y; Amemiya K; Mochizuki H; Tsutsui T; Kakizaki Y; Miyashita Y; Higuchi R; Nakagomi T; Goto T; Oyama T; Omata M
Mol Diagn Ther; 2023 Jul; 27(4):513-523. PubMed ID: 37198423
[TBL] [Abstract][Full Text] [Related]
27. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
28. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
29. Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non-Small Cell Lung Carcinomas.
Lo YC; Bauer AH; Odintsov I; Siegmund SE; Sholl LM; Dong F
Mod Pathol; 2023 May; 36(5):100126. PubMed ID: 36842187
[TBL] [Abstract][Full Text] [Related]
30. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
31. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
32. Cell-Free Circulating Tumour DNA Blood Testing to Detect
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
[TBL] [Abstract][Full Text] [Related]
33. Should Interventional Pulmonologists Take Ownership for Ordering Next-Generation Sequencing and Immunohistochemistries for Patients With Newly Diagnosed Non-Small Cell Lung Cancer?
Mahajan AK; Folch E; Musani A
Chest; 2019 Dec; 156(6):1281-1282. PubMed ID: 31812206
[No Abstract] [Full Text] [Related]
34. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Conde E; Hernandez S; Martinez R; Angulo B; De Castro J; Collazo-Lorduy A; Jimenez B; Muriel A; Mate JL; Moran T; Aranda I; Massuti B; Rojo F; Domine M; Sansano I; Garcia F; Felip E; Mancheño N; Juan O; Sanz J; Gonzalez-Larriba JL; Atienza-Cuevas L; Arriola-Arellano E; Abdulkader I; Garcia-Gonzalez J; Camacho C; Rodriguez-Abreu D; Teixido C; Reguart N; Gonzalez-Piñeiro A; Lazaro-Quintela M; Lozano MD; Gurpide A; Gomez-Roman J; Lopez-Brea M; Pijuan L; Salido M; Arriola E; Company A; Insa A; Esteban-Rodriguez I; Saiz M; Azkona E; Alvarez R; Artal A; Plaza ML; Aguiar D; Enguita AB; Benito A; Paz-Ares L; Garrido P; Lopez-Rios F
J Thorac Oncol; 2019 Dec; 14(12):2120-2132. PubMed ID: 31349061
[TBL] [Abstract][Full Text] [Related]
35. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
[TBL] [Abstract][Full Text] [Related]
36. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
37. Performance of a 50-gene next generation sequencing panel with post-centrifuge supernatant cytology fluid in non-small-cell lung cancer.
Tafoya M; Judd A; Chiotti K; Dearen K; Jiron K; Chabot-Richards D; Broehm CJ
Diagn Cytopathol; 2021 Nov; 49(11):1173-1178. PubMed ID: 34339108
[TBL] [Abstract][Full Text] [Related]
38. FoundationOne CDx detected an uncovered variant of
Takahashi H; Ogino H; Bando H; Mitsuhashi A; Tsukazaki Y; Yabuki Y; Ozaki R; Yoneda H; Sato S; Hanibuchi M; Nishioka Y
Respir Med Case Rep; 2023; 45():101893. PubMed ID: 37485237
[TBL] [Abstract][Full Text] [Related]
39. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
40. Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non-small-cell Lung Cancer.
Stoy SP; Segal JP; Mueller J; Furtado LV; Vokes EE; Patel JD; Murgu S
Clin Lung Cancer; 2018 May; 19(3):230-238.e2. PubMed ID: 29277564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
